Effect of nebivolol on left ventricular function in patients with chronic heart failure: A pilot study

European Journal of Heart Failure

Volumn 4, Issue 6, 2002, Pages 757-763

  Brehm, Bernhard R ^a   Wolf, Sabine C ^a   Görner, Sandra ^a   Buck Müller, Nina ^a   Risler, Teut ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Blocker; Chronic heart failure; Left ventricular function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; PLACEBO;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BENZOPYRANS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART FUNCTION TESTS; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0036896614     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00113-7     Document Type: Article

References (24)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet 1999;353:9-13.
2. US Carvedilol Heart Failure Study Group, Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
3. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
4. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
5. Cockroft JR, Chowenczyk PHJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: Evidence for L-arginin/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
6. Brehm BR, Bertsch D, Wolf SC. Nebivolol hemmt die proliferation sowohl von humanen koronararteriellen glatten muskelzellen als auch von endothelzellen und steigert die NO-freisetzung. Perfusion 1998;11:475-84.
7. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis on human coronary artery smooth muscle and endothelical cells. Cardiovasc Res 2001;49:430-9.
8. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: Protective effects of nebivolol. Eur J Pharmacol 1999;366:223-32.
9. Melin JA, Piret LV, Vanbutsele RJM, et al. Diagnostic value of exercise electrocardiography and thallium myocardial scintigraphy in patients without previous myocardial infarction: A bayesian approach. Circulation 1989;63:1019-24.
10. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
11. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
12. McNeely W, Goa KL. Nebivolol in the management of essential hypertension. Drugs 1999;57:633-51.
13. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: A double-blind randomised trial. J Hum Hypertens 1997;11:813-9.
14. van Bortel LMAB, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drug Ther 1992;6:239-47.
15. Clements IP, Miller WL. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy. Am Heart J 2001;141:259-62.
16. De Cree J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 1987;38:440-8.
17. De Cree J, Cobo C, Geukens H, Verhaegen H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology 1990;41:95-105.
18. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100.
19. Clements IP, Miller WL, Olson LJ. Resting heart rate and cardiac function in dilated cardiomyopathy. Int J Cardiol 1999;72:27-37.
20. Broeders MAW, Doevendans PA, Bekkers BCAM, et al. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-84.
21. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist. Circulation 2000;101:142-7.
22. Love MP, Ferro CJ, Haynes WG, et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 2000;47:166-72.
23. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
24. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.